A Phase 1B Study of ELA026 in People with Secondary Hemophagocytic Lymphohistiocytosis


Full Title

A Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)


Researchers want to find the best dose of ELA026 to use in people with secondary hemophagocytic lymphohistiocytosis (sHLH). When you have sHLH, certain white blood cells become overactive and attack other healthy blood cells. The white blood cells damage your own healthy tissues and organs. sHLH is usually triggered by another disease, such as cancer, infection, or autoimmune disease.

ELA026 targets and kills white blood cells that are acting abnormally. This targeting action may help the immune system return to normal. ELA026 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You or your child must:

  • Be age 6 or older.
  • Have sHLH that has never been treated (for people age 12 and older) or continues to get worse even with treatment.


For more information and to see if you or your child can join this study, please call Dr. William Johnson’s office at 646-608-2091.




Phase I (phase 1)

Disease Status

Relapsed or Refractory


ClinicalTrials.gov ID